Fig 1.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of publications screened.
^ Refers to the update literature search described in this manuscript, January 2016–02 May 2019. *De-duplicated by librarian. + Bush JT, Wasunna M, Alves F, Alvar J, Olliaro PL, Otieno M, et al. (2017) Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform. PLoS Negl Trop Dis 11(9): e0005781. ~ Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org.
Table 1.
Drug regimens tested and number of patients treated for each regimen in the studies included in the review.
Table 2.
Description of deaths adjudicated as related to or probably/possibly related to study drug (n = 60).
Table 3.
Incidence rate of death per 1,000 person-days within the first 30 days of treatment initiation.
Fig 2.
Incidence rate of death within 30 days of treatment initiation.
The left-hand panel presents the pooled estimate of incidence rate of death from random effects meta-analysis with 95% confidence interval. The right-hand panel presents the estimate and 95% confidence interval from analysis which adjusted for potential publication bias; L-AmB = Liposomal amphotericin B; PA = pentavalent antimony; AMBd = amphotericin B deoxycholate.